Treatment of insulin resistance in the neurodegeneration

Recent Patents on CNS Drug Discovery

Volumn 9, Issue 1, 2014, Pages 54-63

  Stefanelli, Manuela ^a   Martocchia, Antonio ^a   De Marinis, Elisabetta Adele ^a   Falaschi, Giulia Maria ^a   Romano, Gloria ^a   Rufo, Maddalena ^a   Falaschi, Paolo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Glucagon like peptide 1; Incretins; Insulin receptors; Insulin resistance; Neurodegeneration

Indexed keywords

ACARBOSE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; FOCAL ADHESION KINASE; GASTRIC INHIBITORY POLYPEPTIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE TRANSPORTER; INCRETIN; INSULIN; INSULIN RECEPTOR; INSULIN SENSITIZING AGENT; LIRAGLUTIDE; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; TRANSCRIPTION FACTOR FOXO; NEUROPROTECTIVE AGENT;

ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; DIABETES MELLITUS; DOWN REGULATION; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME ACTIVATION; GLIA; GLUCOSE METABOLISM; GLUCOTOXICITY; HUMAN; INCIDENCE; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; IONTOPHORESIS; NERVE CELL; NERVE DEGENERATION; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UNITED STATES; ANIMAL; NEURODEGENERATIVE DISEASES; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS;

EID: 84900551898     PISSN: 15748898     EISSN: 22123954     Source Type: Journal    
DOI: 10.2174/1574889809666140410093006     Document Type: Article

References (103)

1. Leeson GW, Harper S. Some descriptive findings from the Global Ageing Survey (GLAS). Investing in Later Life. Oxford Institute of Ageing, University of Oxford. 2008; 108: 1-28.
2. Schrijvers EM, Verhaaren BF, Koudstaal PJ, Hofman A, Ikram MA, Breteler MM. Is dementia incidence declining?: Trends in dementia incidence since 1990 in the Rotterdam Study. Neurology. 2012 May 8;78(19):1456-63. doi: 10.1212/WNL.0b013e3182553be6. Epub 2012 May 2.
3. Batsch NL, Mittelman MS. Alzheimer's disease international overcoming the stigma of dementia. World Alzheimer Report 2012; 1-80.
4. Brands AM, Biessels GJ, de Haan EH, Kappelle LJ, Kessels RP. The effects of type 1 diabetes on cognitive performance: a metaanalysis. Diabetes Care 2005; 28: 726-35
5. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 2006; 5: 64-74.
6. Janson J, Laedtke T, Parisi JE, O'Brien P, Petersen RC, Butler PC. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 2004; 53: 474-81.
7. Li L, Holscher C. Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain Res Rev 2007; 56: 384-402.
8. McCrimmon RJ, Ryan CM, Frier BM. Diabetes and cognitive dysfunction. Lancet 2012; 379: 2291-9.
9. Diabetes mellitus. In: The Merck Manual. 2010-2013 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, N.J., U.S.A.
10. Karmi A, Iozzo P, Viljanen A, Hirvonen J, Fielding BA, Virtanen K, et al. Increased brain fatty acid uptake in metabolic syndrome. Diabetes 2010; 59: 2171-7.
11. Giorda CB, Avogaro A, Maggini M, Lombardo F, Mannucci E, Turco S, et al. Incidence and risk factors for stroke in type 2 diabetic patients: the DAI study. Stroke 2007; 38: 1154-60.
12. Kroner Z. The relationship between Alzheimer's disease and diabetes: Type 3 diabetes? Altern Med Rev 2009; 14: 373-9.
13. Gilman S. Alzheimer's disease. Perspect Biol Med 1997; 40: 230-45.
14. Gotz J, Schild A, Hoerndli F, Pennanen L. Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models. Int J Dev Neurosci 2004; 22: 453-65.
15. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Sci 1992; 256: 184-5.
16. Vetrivel KS, Thinakaran G. Amyloidogenic processing of β-amyloid precursor protein in intracellular compartments. Neurol 2006; 66: S69-S73.
17. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001; 81: 741-66.
18. Small DH, Mok SS, Bornstein JC. Alzheimer's disease and Aβ toxicity: from top to bottom. Nat Rev Neurosci 2001; 2: 595-8.
19. Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, et al. Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline. JAMA 2000; 283: 1571-7.
20. Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci USA 1999; 96: 3228-33.
21. Johnson GV, Stoothoff WH. Tau phosphorylation in neuronal cell function and dysfunction. J Cell Sci 2004; 117: 5721-9.
22. Cotman CW, Poon WW, Rissman RA, Blurton-Jones M. The role of caspase cleavage of tau in Alzheimer disease neuropathology. J Neuropathol Exp Neurol 2005; 64: 104-12.
23. Rohn TT, Rissman RA, Davis MC, Kim YE, Cotman CW, Head E. Caspase-9 activation and caspase cleavage of tau in the Alzheimer's disease brain. Neurobiol Dis 2002; 11: 341-54.
24. Chung CW, Song YH, Kim IK, Yoon WJ, Ryu BR, Jo DG, et al. Proapoptotic effects of tau cleavage product generated by caspase-3. Neurobiol Dis 2001; 8: 162-72.
25. Gamblin TC, Berry RW, Binder LI. Tau polymerization: role of the amino terminus. Biochem 2003; 42: 2252-7.
26. Hrnkova M, Zilka N, Minichova Z, Koson P, Novak M. Neurodegeneration caused by expression of human truncated tau leads to progressive neurobehavioural impairment in transgenic rats. Brain Res 2007; 1130: 206-13.
27. Rocchi A, Pellegrini S, Siciliano G, Murri L. Causative and susceptibility genes for Alzheimer's disease: a review. Brain Res Bull 2003; 61: 1-24.
28. Reddy VP, Zhu X, Perry G, Smith MA. Oxidative stress in diabetes and Alzheimer's disease. J Alzheimers Dis 2009; 16: 763-74.
29. Hoyer S. Is sporadic Alzheimer disease the brain type of noninsulin dependent diabetes mellitus? A challenging hypothesis. J Neural Transm 1998; 105: 415-22.
30. Nelson TJ, Alkon DL. Insulin and cholesterol pathways in neuronal function, memory and neurodegeneration. Biochem Soc Trans 2005; 33: 1033-6.
31. Zhao WQ, Townsend M. Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. Biochim Biophys Acta 2009; 1792: 482-96.
32. Martins IJ, Hone E, Foster JK, Sünram-Lea SI, Gnjec A, Fuller SJ, et al. Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. Mol Psychiatr 2006; 11: 721-36.
33. De la Monte SM, Wands JR. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. J Alzheimers Dis 2005; 7: 45-61.
34. Catalano SM, Dodson EC, Henze DA, Joyce JG, Krafft GA, Kinney GG. The role of amyloid-β derived diffusible ligands (ADDLs) in Alzheimer's disease. Curr Top Med Chem 2006; 6: 597-608.
35. Gasparini L, Xu H. Potential roles of insulin and IGF-1 in Alzheimer's disease. Trends Neurosci 2003; 26: 404-6.
36. Frolich L, Blum-Degen D, Bernstein HG, Engelsberger S, Humrich J, Laufer S, et al. Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm 1998; 105: 423-38.
37. Kim B, Backus C, Oh S, Hayes JM, Feldman EL. Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes. Endocrinol 2009; 150: 5294-301.
38. Ke YD, Delerue F, Gladbach A, Gotz J, Ittner LM. Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer's disease. PLoS One 2009; 4: e7917. doi: 10.1371/journal.pone.0007917.
39. Li ZG, Zhang W, Sima AA. Alzheimer-like changes in rat models of spontaneous diabetes. Diabetes 2007; 56: 1817-24.
40. Liu Y, Liu F, Grundke-Iqbal I, Iqbal K, Gong CX. Brain glucose transporters, O-GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer disease. J Neurochem 2009; 111: 242-9.
41. Jolivalt CG, Hurford R, Lee CA, Dumaop W, Rockenstein E, Masliah E. Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic mice. Exp Neurol 2010; 223: 422-31.
42. Takeda S, Sato N, Uchio-Yamada K, Sawada K, Kunieda T, Takeuchi D, et al. Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci USA. 2010; 107: 7036-7041.
43. El Khoury NB, Gratuze M, Papon MA, Bretteville A, Planel E. Insulin dysfunction and Tau pathology. Front Cell Neurosci 2014; 8: 22.
44. Dias WB, Hart GW. O-GlcNAc modification in diabetes and Alzheimer's disease. Mol Biosyst 2007; 3: 766-72.
45. Domínguez RO, Pagano MA, Marschoff ER, González SE, Repetto MG, Serra JA. Alzheimer disease and cognitive impairment associated with diabetes mellitus type 2: Associations and a hypothesis. Neurologia 2013; S0213-4853(13)00155-2. doi: 10.1016/j.nrl.2013.05.006.
46. Augustin R. The protein family of glucose transport facilitators: it's not only about glucose after all. IUBMB Life 2010; 62: 315-33.
47. Vannucci S, Koehler-Stec E, Kang L, Reynolds T, Clark R, Simpson I. GluT4 glucose transporter expression in rodent brain: effect of diabetes. Brain Res 1998; 797: 1-11.
48. Grillo CA, Piroli GG, Hendry RM, Reagan LP. Insulin-stimulated translocation of GLUT4 to the plasma membrane in rat hippocampus is PI3-kinase dependent. Brain Res 2009; 1296: 35-45.
49. Huang Y, Lei L, Liu DG, Jovin I, Russell R, Johnson RS, et al. Normal glucose uptake in the brain and heart requires an endothelial cell-specific HIF-1 β -dependent function. Proc Natl Acad Sci 2012; 109: 17478-83.
50. Winocur G, Greenwood CE, Piroli GG, Grillo CA, Reznikov LR, Reagan LP, et al. Memory impairment in obese Zucker rats: An investigation of cognitive function in an animal model of insulin resistance and obesity. Behavior Neurosci 2005; 119: 1389-95.
51. De la Monte SM. Intranasal insulin therapy for cognitive impairment and neurodegeneration: current state of the art. Expert Opin Drug Deliv 2013; 10: 1699-709.
52. Brünner YF, Benedict C, Freiherr J. Targeting the brain through the nose. Effects of intranasally administered insulin. Nervenarzt 2013; 84: 949-54. doi: 10.1007/s00115-013-3806-8.
53. Hallschmid M, Schultes B. Central nervous insulin resistance: a promising target in the treatment of metabolic and cognitive disorders? Diabetol 2009; 52:2264-9.
54. Wozniak M, Rydzewski B, Baker SP, Raizada MK. The cellular and physiological actions of insulin in the central nervous system. Neurochem Int 1993; 22: 1-10.
55. Urich E, Lazic SE, Molnos J, Wells I, Freskgard PO. Transcriptional profiling of human brain endothelial cells reveals key properties crucial for predictive in vitro blood-brain barrier models. PLoS ONE 2012; 5: e38149. doi:10.1371/journal.pone.0038149.
56. Ban WA. Brain meets body: the blood-brain barrier as an endocrine interface. Endocrinol 2012; 153: 4111-9.
57. Heni M, Schopfer P, Peter A, Sartorius T, Fritsche A, Synofzik M, et al. Evidence for altered transport of insulin across the bloodbrain barrier in insulin-resistant humans. Acta Diabetol 2013; Epub ahead of print.
58. De La Monte SM. Metabolic derangements mediate cognitive impairment and Alzheimer's disease: role of peripheral insulinresistance diseases. Panminerva Med 2012; 54: 171-8.
59. Pedersen WA, McMillan PJ, Kulstad JJ, Leverenz JB, Craft S, Haynatzki GR. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol 2006; 199: 265-73.
60. Kappe C, Tracy LM, Patrone C, Iverfeldt K, Sjöholm Å. GLP-1 secretion by microglial cells and decreased CNS expression in obesity. J Neuroinflammation 2012; 9: 276. doi: 10.1186/1742-2094-9-276.
61. De La Monte SM, Longato L, Tong M, Wands JR. Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis. Curr Opin Investig Drugs 2009; 10: 1049-60.
62. Drucker DJ. The role of gut hormones in glucose homeostasis. J Clin Invest 2007; 117: 24-32.
63. Laakso M, Zilinskaite J, Hansen T, Boesgaard TW, Vanttinen M, Stancakova A, et al. Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study. Diabetol 2008; 51: 502-11.
64. Williams DL. Minireview: finding the sweet spot: peripheral versus central glucagon-like peptide 1 action in feeding and glucose homeostasis. Endocrinol 2009; 150: 2997-3001.
65. Perry T, Holloway HW, Weerasuriya A, Mouton PR, Duffy K, Mattison JA, et al. Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp Neurol 2007; 203: 293-301.
66. Darsalia V, Mansouri S, Ortsater H, Olverling A, Nozadze N, Kappe C, et al. Glucagon-like peptide-1 receptor activation reduces ischemic brain damage following stroke in type 2 diabetic rats. Clin Sci (Lond) 2012; 122: 473-83.
67. Li Y, Duffy KB, Ottinger MA, Ray B, Bailey JA, Holloway HW, et al. GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J Alzheimers Dis 2010; 19: 1205-19.
68. During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003; 9: 1173-9.
69. Isacson R, Nielsen E, Dannaeus K, Bertilsson G, Patrone C, Zachrisson O, et al. The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test. Eur J Pharmacol 2011; 650: 249-55.
70. Bertilsson G, Patrone C, Zachrisson O, Andersson A, Dannaeus K, Heidrich J, et al. Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J Neurosci Res 2008; 86: 326-38.
71. Kapogiannis, D. A clinical trial of exendin-4 for the treatment of Alzheimer's disease. NCT01255163 (2012).
72. Egefjord L, Gejl M, Møller A, Brændgaard H, Gottrup H, Antropova O, et al. Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer's disease-protocol for a controlled, randomized double-blinded trial. Dan Med J 2012; 59 (10): A4519.
73. Brock, B. Neurodegenerative Changes in Alzheimer's Disease: Identifying Potential Effects of Liraglutide on Degenerative Changes. NCT01469351 (2013).
74. Vrang N, Hansen M, Larsen PJ, Tang-Christensen M. Characterization of brainstem preproglucagon projections to the paraventricular and dorsomedial hypothalamic nuclei. Brain Res 2007; 1149: 118-26.
75. Iwai T, Ito S, Tanimitsu K, Udagawa S, Oka J. Glucagon-like peptide-1 inhibits LPS-induced IL-1beta production in cultured rat astrocytes. Neurosci Res 2006; 55: 352-60.
76. Chen S, An FM, Yin L, Liu AR, Yin DK, Yao WB, et al. Glucagon-like peptide-1 protects hippocampal neurons against advanced glycation end product-induced tau hyperphosphorylation. Neurosci 2013; 256C:137-146.
77. Gupta A, Dey CS. PTEN, a widely known negative regulator of insulin/PI3K signaling, positively regulates neuronal insulin resistance. Mol Biol Cell 2012; 23: 3882-98.
78. Newton AC, Trotman LC. Turning off AKT: PHLPP as a drug target. Annu Rev Pharmacol Toxicol 2014; 54: 537-58. doi: 10.1146/annurev-pharmtox-011112-140338.
79. Tikhanovich I, Cox J, Weinman S. FOXO transcription factors in liver function and disease. J Gastroenterol Hepatol 2013; 28: 125-131. doi:10.1111/jgh.12021.]
80. Hoyer S. Is sporadic Alzheimer's disease the brain type of noninsulin dependent diabetes mellitus? A challenging hypothesis. J Neural Transm 1998; 105: 415-22.
81. Prediabetes and the potential to prevent diabetes. Lancet 2012; 379: 2213. doi:10.1016/S0140-6736(12)60960-X
82. De La Monte SM. Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease. Drugs 2012; 72: 49-66. doi: 10.2165/11597760-000000000-00000.
83. Duarte AI, Candeias E, Correia SC, Santos RX, Carvalho C, Cardoso S, et al. Crosstalk between diabetes and brain: glucagonlike peptide-1 mimetics as a promising therapy against neurodegeneration. Biochim Biophys Acta 2013; 1832: 527-41
84. So Ra K, Dae-Hoon K, Soo Hyun P, Young Seok K, Chun Hwa K, Tae-Young H, et al. Efficacy of HD0471953: A Novel GPR119 Agonist for the Treatment of Type 2 Diabetes Mellitus Journal of Diabetes Research Volume 2013, Article ID 269569, 6 pages doi.org/10.1155/2013/269569
85. Yang Y, Zhang J, Ma D, Zhang M, Hu S, Shao S, et al. Subcutaneous administration of liraglutide ameriolates Alzheimer associated tau hyperphosphorylation in rats with type 2 diabetes. J Alzheimers Dis 2013; 37: 637-48.
86. Egefjord L, Gejl M, Moller A, Braendgaard H, Gottrup H, Moler N, et al. Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer's disease-protocol for a controlled, randomized double-blinded trial. Dan Med J 2012; 59: A4519.
87. Sharma MK, Jalewa J, Hölscher CJ. Neuroprotective and antiapoptotic effects of Liraglutide on SH-SY5Y cells exposed to methylglyoxal stress. J Neurochem 2013. doi: 10.1111/jnc.12469. [Epub ahead of print]
88. Kuzma, P., Decker, S., Quandt, H. Sustained delivery of exenatide and other polypeptides. US20130252894A1 (2013).
89. Boehm, M.F., Martinborough, E., Moorjani, M., Tamiya, J., Huang, H., Yeager, A., Brahmachary, E., Fowler, T., Novak, A., Meghani, P., Knaggs, M. Novel Glp-1 receptor modulators. WO2013090454A2 (2013).
90. Duffy AM, Hölscher C. The incretin analogue D-Ala2GIP reduces plaque load, astrogliosis and oxidative stress in an APP/PS1 mouse model of Alzheimer's disease. Biochem Med (Zagreb) 2013; 23: 266-80.
91. D'Amico M. Long term inhibition of dipeptyl peptidase-4 in Alzheimer's prone mice. Exp Gerontol 2010; 45: 202-7.
92. Yoon SY, Choi JE, Huh JW, Hwang O, Nam Hong H, Kim D. Inactivation of GSK-3beta in okadaic acid.induced neurodegeneration: relevance to Alzheimer's disease. Neuroreport 205; 16: 223-7.
93. Kim DH, Huh JW, Jang M, Suh JH, Kim TW, Park JS. Sitagliptin increases tau phosphorylation in the hippocampus of rats with type 2 diabetes and in primary neuron cultures. Neurobiol Dis 2012; 46(1): 52-8. doi: 10.1016/j.nbd, 2011.12.043
94. Savchuk, N.F., Tkachenko, S.Y., Nazarenkov, D.Y. Incretin hormone secretion stimulators, method for producing and using same. WO2013161622A3 (2013).
95. Bradley, K., Elkes, R., Fitzpatrick, S., Kendall, R., Saklatvala, R., Mohammed, M. Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with simvastatin. WO2012173877A1 (2012).
96. Eickelmann, P., Luippold, G., Mark, M., Thomas, L. Combination of a GPR119 agonist and the DPP-IV inhibitor linagliptin for use in the treatment of diabetes and related conditions US20130109703A1(2013).
97. Yamanaka M, Ishikawa T, Griep A, Axt D, Kummer MP, Heneka MT. PPAR/RXR-induced and CD36-mediated microglial amyloid-β phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice. J Neurosci 2012; 28; 32(48): 17321-31. doi: 10.1523/JNEUROSCI.1569-12.2012.
98. Benedict C, Frey WH 2nd, Schiöth HB, Schultes B, Born J, Hallschmid M. Intranasal insulin as a therapeutic option in the treatment of cognitive impairments. Exp Gerontol 2011; 46: 112-5.
99. Craft S, Baker LD, Montine TJ, Minoshima S, Watson S, Claxton A. Intranasal insulin therapy for alzheimer disease and amnestic mild cognitive impairment. Arch Neurol 2012; 69(1): 29-38. doi:10.1001/archneurol.2011.233.
100. Lia Y, Duffyb KB, Ottingerb MA, Rayc B, Baileyc JA, Hollowaya HW, et al. GLP-1 Receptor stimulation reduces amyloid-β peptide accumulation and cytotoxicity in cellular and animal models of alzheimer's disease. J Alzheimers Dis 2010; 19(4): 1205-19. doi:10.3233/JAD-2010-1314
101. Shantha, T.R. Alzheimer's disease treatment with multiple therapeutic agents delivered to the olfactory region through a special delivery catheter and iontophoresis. US20140012182A1 (2014).
102. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. "Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man". Diabetol 1985; 28(7): 412-9. doi:10.1007/BF00280883.
103. Paul, E. Evaluating Liraglutide in Alzheimer's Disease (ELAD). NCT01843075 (2013).